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Abstract: 
Cyclooxygenase-2 (COX-2) enzyme binds to arachidonic acid and releases metabolites that are used to induce pain and 
inflammation. COX-2 selective inhibitors such as celecoxib, rofecoxib and valdecoxib are currently used to reduce inflammatory 
response. However, they lack anti-thrombotic activity and hence lead to cardiovascular and renal liabilities apart from 
gastrointestinal irritation. Therefore, there is still a need to develop more potent COX-2 inhibitors. In this paper, we report the 
screening of various compounds from the ZINC database (contains 4.6 million small molecule compounds) using the eHiTS 
(electronic High Throughput Screening) software tool against the COX-2 protein. The strategy employed can be conveniently split 
into two categories, viz. screening and docking, respectively. Screening was performed using molecular constraints tool to filter 
compounds with physico-chemical properties similar to the 6COX bound ligand SC-558. The analysis resulted in 1042 Lipinski 
compliant hits which are docked and scored to identify structurally novel ligands that make similar interactions to those of known 
ligands or may have different interactions with other parts of the binding site. Our screening approach identified two molecules 
ZINC00663976 (eHITS score of -7.135 kcal/mol) and ZINC02062094 (eHITS score of -7.242 kcal/mol) from the ZINC database. 
Their energy scores are better than the 6COX bound co-crystallized ligand SC-558 with an eHiTS score of -6.559 kcal/mol. Both the 
ligands were docked within the binding pocket forming interactions with Leu352, Phe518, Met522, Val523, Ala527 and Ser353. 
Visual inspection suggested similar orientation and binding mode for ZINC02062094 with SC-558 ligand. The NH group of the 
ligand formed hydrogen bond interactions with the backbone NH of Ala527.  
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Background: 
COX-2 is expressed after an inflammatory stimulus and 
releases metabolites that are used to induce pain and 
inflammation. During normal physiology, COX-2 levels are 
undetectable whereas during periods of acute and chronic 
inflammation, the level of COX-2 is significantly higher. 
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) exhibit 
their effect through inhibition of cyclooxygenase (COX) 
enzymes by blocking the synthesis of prostaglandins from 
arachidonic acid [1]. Conventional NSAIDs are profoundly 
used in the treatment of wide variety of inflammatory 
conditions and they act by the inhibition of cyclooxygenase 
(COX), the enzyme involved in the biosynthesis of 
prostaglandins, prostacyclins and thromboxanes from 
arachidonic acid [2, 3].  
 
It has been shown recently that the COX enzyme exists in 
three isoforms - COX-1, COX-2 and COX-3. COX-1 primarily 
responsible for cytoprotection and COX-2, the inducible form 
is associated with inflammation, whereas, COX-3 has no 
importance in the development of inflammation. COX-1 
enzyme is responsible for maintaining homeostasis (gastric 
and renal integrity), whereas COX-2 induces the inflammatory 
symptoms in response to inflammatory stimuli [4]. The two 
COX isoforms are about 60% homologous. The ability to 
inhibit one isoform selectively is attributed to the different 
amino acids at position 523, isoleucine in COX-1 and valine in 
COX-2  [5]. Therefore, selective COX-2 inhibition would 
reduce the undesired side effects such as gastro-intestinal 
disorders, ulcers and renal failure [6].  
 
Several classes of compounds having selective COX-2 
inhibitory activity have been reported in the literature, for 
example, diaryl heterocylics as oxazoles, thiophens, pyrazoles, 
imidazoles [7], and common classical agents modified to have 
selective COX-2 inhibitory activity such as esters and amides 
of indomethacin and meclofenamic acid [4]. The classical 
NSAIDs produce their adverse effects via inhibition of COX-1 
isoform, hence many investigations have been directed to find 
compounds able to act as selective COX-2 inhibitors such as 
6COX bound SC-558, celecoxib, rofecoxib, valdecoxib and 
more recently, nitroxy substituted 1,5-diarylimidazoles [8], 
phenylazobenzenesulfonamides  [9], respectively. However, 
evidence suggests that adverse reactions such as gastro-
intestinal irritation or ulceration and renal liabilities are 
associated with prolonged use of COX-2 selective inhibitors 
[10]. These inhibitors are also known to suppress synthesis of 
prostacyclin, a potent vasodilator, gastroprotectant, and 
platelet inhibitor, via the inhibition of endothelial COX-2. The 
COX-2 selective inhibitors intrinsically lack anti-thrombotic 
activity and some cardiovascular liabilities have been found 
associated with them in preclinical studies [11]. Thus, there is 
still a need for novel, selective, and potent COX-2 inhibitors Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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with an improved profile compared to current COX-2 
inhibitors. 
 
Traditional synthesis of a series of new compounds utilizing 
combinatorial chemistry and high-throughput screening can be 
carried out at high cost and also are time consuming; whereas 
on the other hand, screening small molecule databases for 
novel compounds represents an alternative process. Docking 
various ligands to the protein of interest followed by scoring to 
determine the affinity of binding and to reveal the strength of 
interaction has become increasingly important in the context of 
drug discovery. Screening large databases of compounds can 
provide a feasible, alternative technique against high-
throughput screening, but depends on the fast and accuracy of 
the docking algorithm. Hence, in this paper we report 
screening a library of compounds from ZINC database [12] 
against COX-2 protein, 6COX (PDB ID) with bound ligand 
SC-558 extracted from protein data bank, by utilizing a fast, 
exhaustive docking software eHiTS (electronic High 
Throughput Screening) [13].  
 
Virtual screening is now established as an effective paradigm 
for filtering compounds for drug discovery process [14]. The 
technique employed is based on the prediction of binding 
modes and binding affinities of each compound in the dataset 
by means of docking to an X-ray crystallographic structure. 
Virtual screening utilizes docking and scoring of each 
compound from a dataset. Some recent studies [15] have 
focused on certain crucial factors such as the size and diversity 
of the ligand dataset, wide range of targets and the evaluation 
of docking programs. Various studies reported in literature 
stated the importance of dataset size such as 10,000 
compounds using FlexX [16], 44,000 compounds using 
Surflex [17] and several others. 
 
In general, it is important to visualize the docked poses of 
high-scoring compounds because many ligands are docked in 
different orientations and may often miss interactions that are 
known to be important for the target receptor. This sort of 
study becomes more difficult as the size of the dataset 
increases. Therefore, an alternative approach is to eliminate 
unpromising compounds before docking by restricting the 
dataset to drug-like compounds, by filtering the dataset based 
on appropriate property and sub-structural features and by 
performing diversity analysis. These approaches can be highly 
effective in reducing the dataset to be docked to the order of 
10
3 to 10
4 compounds [18]. 
 
Methodology: 
Receptor X-ray structure 
The 3D coordinates of the crystal structure of COX-2 in 
complex with SC-558 inhibitor (PDB code: 6COX)  was 
selected as the receptor model in virtual screening program. 
We used the chemical compound library, ZINC database and 
the docking program eHiTS for the study.  
 
Ligand ZINC database 
ZINC, an acronym for ‘ZINC is not commercial, a free 
database for virtual screening’ contains over 4.6 million 
compounds in ready-to-dock, 3D formats, available at the URL 
http://zinc.docking.org. Molecules in ZINC are annotated by 
molecular property that include molecular weight, number of 
rotatable bonds, calculated LogP, number of hydrogen-bond 
donors, hydrogen-bond acceptors, chiral centers, chiral double 
bonds (E/Z isomerism), polar and apolar desolvation energy 
(in kcal/mol), net charge and rigid fragments. The database 
contains 494,915 Lipinski compliant molecules and 202,134 
‘lead-like’ molecules, having molecular weight in the range 
150 to 350 with calculated LogP < 4, number of hydrogen-
bond donors ≤ 3 three, and number of hydrogen-bond 
acceptors ≤ 6. ZINC provides several search criteria such as 
molecular property constraint, ZINC codes, vendor based, and 
molecular substructure search. 
 
eHiTS software 
eHiTS (http://www.simbiosys.ca) has a novel flexible ligand 
docking method that is exhaustive on the conformations and 
poses that avoid severe steric clashes between receptor and 
ligand. The algorithm generates all major docking modes that 
are compatible with the steric and chemistry constraints. First, 
the binding pocket is determined by building a steric grid for 
the whole receptor, dividing regions into separate pockets and 
identifying the possible interaction sites. Then, a cavity 
description is built that consists of thousands of geometric 
shapes (polyhedra). The ligand is divided into rigid fragments 
and connecting flexible chains. The eHiTS docks all rigid 
fragments to all possible places in the cavity independently of 
each other.  
 
Screening 
An exhaustive matching of compatible rigid fragment pose sets 
is performed by a rapid hyper-graph clique detection 
algorithm. This yields a few hundred to several million 
acceptable combinations of poses. This approach makes the 
search exhaustive, i.e., it finds all possible solutions. The 
accuracy is set to the highest (accuracy = 6) during docking. 
eHiTS has three different scoring functions: (a) a simple and 
fast chemical flag based statistical scoring function; (2) 
empirical-scoring function and (3) a third scoring function that 
combines both statistical and empirical components along with 
grid based geometrical terms, entropy loss estimation and 
receptor surface area. To visualize different poses, CheVi 
software, a graphical user interface was utilized. 
 
Before screening ZINC database, the docking protocol was 
validated. 6COX protein bound ligand SC-558 was docked 
into the binding pocket to obtain the docked pose and the 
RMSD (Root Mean Square Deviation) of all atoms between 
these two conformations is 0.51 Å indicating that the 
parameters for docking simulation are good in reproducing the 
X-ray crystal structure. Therefore, the ZINC database was 
screened for compounds similar to SC-558 structural features 
(structure based search) and by providing molecular 
constraints (property based search). The physico-chemical 
properties such as log P value, H-bond donors, H-bond 
acceptors, molecular weight and rotational bonds, for SC-558 
ligand are calculated using the ADME/Tox filter server [19].  
 
Discussion: 
We searched the ZINC database using structural features that 
are similar to SC-558 and no hit was obtained. We then 
repeated the search based on property and identified 1042 hits 
that are Lipinski [20] compliant.We docked these 1042 
compunds using eHITS and evaluated binding compatibility Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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with the receptor based on docked energy (in kcal/mol). The 
docking tool generated 32 conformers for each docked 
molecule in about 1-2 minutes of CPU time. The virtual 
screening technique employed in this study identified diverse, 
yet specific ligands that bind in a comparable manner similar 
to SC-558 binding for COX-2. This approached identified two 
compounds ZINC00663976 and ZINC02062094 from the 
ZINC database for compatible binding with COX-2 (Table 1 in 
supplementary material). 
 
SC-558, a diaryl heterocyclic inhibitor has 1900-fold 
selectivity for COX-2 over COX-1. It has a central pyrazole 
ring and a sulphonamide substituent attached to one of the aryl 
rings. The bromophenyl ring of SC-558 is bound in a 
hydrophobic cavity formed by Phe381, Leu384, Tyr385, 
Trp387, Phe518, Met522, Val523 and Ser530. The 
trifluoromethyl group is bound in an adjacent pocket formed 
by Met113, Val116, Val349, Tyr355, Leu359 and Leu531. The 
sulphonamide group extends into a relatively polar region and 
interacts with His90, Gln192, Leu352 and Ser353. One of the 
oxygen atoms of SC-558 forms a hydrogen bond to NE2 atom 
of His90 and the amide nitrogen forms three hydrogen bonds 
to OE1 of Gln192, and carbonyl oxygens of Leu352 and 
Ser353, respectively. These features of SC-558 binding are 
quite important in studying the binding modes of various 
selective and non-selective COX-2 inhibitors. 
 
Binding modes 
The surface point types of two ligands along with their docked 
energies are given in Table 1 (see supplementary material). 
Active site of COX-2 offers many different binding modes for 
these compounds as they are strongly dependent on the 
attached substituent. Both the ligands were docked deeply 
within the binding pocket region forming interactions with 
Leu352, Phe518, Met522, Val523, Ala527 and Ser353, 
respectively. In Table 1 (under supplementary material), the 
binding affinities and the possible number of interactions 
based on chemical property identifiers (surface point types) are 
reported. Our screening approach identified two molecules 
ZINC00663976 (eHITS score of -7.135 kcal/mol) and 
ZINC02062094 (eHITS score of -7.242 kcal/mol) from the 
ZINC database. Their energy scores are better than the 6COX 
bound co-crystallized ligand SC-558 with an eHiTS score of -
6.559 kcal/mol. 
 
The orientation of the docked pose of ZINC00663976 suggests 
that the binding site was partially unoccupied due to lack of 
substitutions on the molecule. The trifluoro substitution of 
ZINC00663976 is oriented towards bromophenyl ring region 
and the halogen substituted benzene ring occupied polar 
region. The other molecule, ZINC02062094 occupied all the 
three pocket regions and represented similar binding modes as 
observed with SC-558. But the NH group of ligand formed one 
hydrogen bond interaction with backbone NH of Ala527. 
Apart from this, scoring system in eHiTS generated 26 
interactions between protein and ligand. The scoring in eHiTS 
is a statistically derived empirical scoring function and is 
based on interaction of 23 distinct surface point [13] types 
between receptor and ligand. In other words, the interaction 
between ligand surface points and receptor surface points 
determine the score of each fragment and on summation 
delivers the final score for the entire ligand.  
 
COX-2 co-crystallized SC-558 ligand resulted in a e-HITS 
dock score of -6.559 kcal/mol. Therefore, any molecule from 
the dataset which shows a score lower than -6.559 kcal per mol 
would be regarded as much interest. Table 1 (see 
supplementary material) gives two such ligands having lower 
binding energies than SC-558. In other words, these two zinc 
ligands would act as inhibitors against COX-2 protein and 
such screening analysis forms the basis when millions of 
ligands are available in compound libraries such as the ZINC 
database.  
 
Interaction of all the 3 compounds (ZINC00663976 and 
ZINC02062094 and co-crystallized SC-558 ligand molecules) 
with the active site residues are presented in Figure 1. The 
specific interactions between active site residues and ligand 
atoms are represented as dotted lines. 
 
Conclusion: 
Virtual screening methods are routinely and extensively 
used to reduced cost and time of drug discovery. It has been 
clearly demonstrated that the approach utilized in this study 
is successful in finding two novel COX-2 inhibitors from 
the ZINC database. ZINC02062094, in particular, showed 
high binding affinity with a e-HITS dock score of -7.242 
kcal/mol against 6COX. The docked pose resembles similar 
orientation as observed with SC-558 ligand. The ligand was 
docked deeply within the binding pocket region forming 
interactions with Leu352, Phe518, Met522, Val523, Ala527 
and Ser353, respectively. Therefore, this study states the 
importance of small molecule libraries and their use to 
enhance drug discovery process prior synthesis. This 
approach to screen novel compounds as COX-2 inhibitors 
from ZINC database depends on various parameters such as 
Lipinski’s rule of 5, pharmacophoric groups attached on the 
ligand, size of the dataset and compound libraries among 
others. Further, work can be extended to study the receptor-
ligand interactions experimentally and evaluation of their 
biological activity would help in designing compounds 
based on virtual screening techniques.Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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Figure 1: Interaction of all the 3 compounds with the active site residues of 6COX a) SC-558 ligand displaying 3 H-bond 
interactions b) ZINC02062094 ligand showing the H-bond interaction between NH group of ligand and backbone NH of Ala527 c) 
ZINC00663976 ligand showing one H-bond interaction between cyano group of ligand and hydroxyl group of Ser530. 
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Table 1: Interaction parameters of COX-2 with the predicted ligand ZINC00663976 and ZINC02062094 and co-crystallized SC-
558 ligand molecules. 
 